Tue, 05th Jul 2022 15:51
ValiRx PLC - Nuneaton, England-based drug development company - Announces that the broker option granted to Turner Pope Investments Ltd has been fully subscribed and raises GBP1.0 million before expenses.
Current stock price: 10.97 pence, up 2.1% on Tuesday in London
12-month change: down 43%
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
(Alliance News) - ValiRx PLC on Thursday said that it has signed an evaluation deal with Imperial College London to look at research on novel therapeu...
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...
(Alliance News) - ValiRx PLC on Tuesday said a requisition notice, which it received earlier in February, has been confirmed as invalid following lega...
(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.
ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Signs agreement with Dundee University's drug ...
ValiRx (VAL)